Health Trials

About this trial

This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).

Eligibility criteria

Qualifiers

are inpatients or outpatients;

demonstrate capacity to consent according to the MacArthur competence assessment tool for clinical research (MacCAT-CR);

have a DSM-5 diagnosis of Schizophrenia or Schizoaffective Disorder for at least 2 years, as determined by the MINI International Neuropsychiatric Interview - Version 7 (MINI-7.0);

are 18 years of age or older;

Disqualifiers

have a history of MINI diagnosis of a substance use disorder (other than nicotine and caffeine) within the past three months;

have a concomitant major unstable medical illness;

are pregnant or intend to get pregnant during the study;

have probable dementia based on study investigator assessment;

Trial design

Treatments tested in this trial

  • Magnetic Seizure Therapy (MST)
  • Electroconvulsive Therapy (ECT)

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

2
University of British Columbia HospitalV6T 2A1, VancouverBritish Columbia, Canada
Centre for Addiction and Mental HealthM6J 1H4, TorontoOntario, Canada

Sponsors and collaborators

Centre for Addiction and Mental Health

Lead sponsor

University of British Columbia

Collaborator

Source ClinicalTrials.gov